LEACHABLES AND VIRUSES
This article was originally published in The Gold Sheet
...are two pharmaceutical product contaminants that are drawing close attention from FDA and industry. For both concerns, an effort is being made to develop more meaningful regulatory standards and guidance that will reflect the potential and the limitations of evaluation and control technologies. Public meetings have been held recently to help facilitate this process. Though the risk is considered very low, TSE is another contamination problem area creating regulatory concern particularly for biologic products. The agency has an "action plan" to try and address the dilemmas involved with TSE and recently issued a revised guidance on preventive measures for blood products.
You may also be interested in...
Drug manufacturers are adopting QbD but there are exceptions, especially among some generics firms, McKinsey finds in industry survey. The top challenge to further adoption: misalignment between R&D and commercial operations. Second is a lack of belief in the business case. However, the cost turns out to be low and the financial reward high, McKinsey says.
Using QbD to set specs that make a difference to patients is hard but important work, FDA's Woodcock says. Prasugrel, levothyroxine, pallodone examples explored. How to establish a 'work space.' How to make the right correlations.
As biotech firms begin to pilot QbD they wrestle with FDA over non-critical process parameters, postapproval changes and more. They are exploring how to define design spaces, change them, identify their edges. And they're still wondering what regulatory relief they might get in return for investing in quality-by-design studies.